Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Latest from Memorial Sloan Kettering Cancer Center


Weekly Carfilzomib Quadruplet Induces High Rates of MRD Negativity, PFS in Newly Diagnosed Myeloma

May 11, 2021

The quadruplet combination comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab was linked with high rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma.

Copanlisib/Rituximab Improves PFS in Relapsed Indolent Non-Hodgkin Lymphoma

April 10, 2021

The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

CheckMate-9ER Sets the Bar for Research With Triplets, Response-Guided Therapy in mRCC

April 02, 2021

Data from the phase 3 CheckMate-9ER trial has not only confirmed the advantage of cabozantinib plus nivolumab in terms of progression-free survival, overall survival, and responses vs sunitinib in the frontline treatment of patients with advanced renal cell carcinoma, but it has served as additional incentive to push the needle even further with research aimed at evaluating triplet regimens in the frontline setting and response-guided sequencing strategies.